Ellex 2RT
Ellex 2RT™ is a research project to develop a non-damaging laser treatment that stimulates the RPE to preserve vision. As a possible therapy for early AMD and other retinal diseases, Ellex 2RT aims to treat the cause of the disease, before vision loss occurs.
RECENT WEBINARS
“Photoregeneration” - Tissue Interaction and Mechanisms of Action
Author: Professor John Marshall, PhD
Professor Marshall will explain the mechanisms of action behind Selective Laser Trabeculoplasty and their relationship to emerging non-thermal therapies for restoring retinal function.
Presentation given at the 2007 AAO.
DOWNLOADS
RECENT PRESS RELEASES
10 NOV 2007
ELLEX 2RT STUDY DEMONSTRATES CLINICAL EFFICACY IN TREATMENT OF DIABETIC MACULAR EDEMA
Ellex today announced clinical results of an ongoing study for non-thermal Retina Regeneration Therapy (Ellex 2RT™).
Read more
1 NOV 2007
ELLEX ANNOUNCES NEW RETINA REGENERATION THERAPY TO BE PRESENTED AT THE AAO
Ellex today announced that the initial results of treating patients with Retina Regeneration Therapy (Ellex 2RT™) will be presented by Peter Hamilton MD, FRCOph at the annual meeting of the American Academy of Ophthalmology.
Read more
2RT IN THE MEDIA
LASER TREATMENT SHOWS PROMISE FOR DIABETIC MACULAR EDEMA
Retina Today, July/August 2008
NEW LASER THERAPY QUICKLY HALTS DIABETIC MACULOPATHY: 2RT TREATS DISEASE EARLY & LEAVES PHOTORECEPTORS UNHARMED
Ophthalmology Times Europe, April 2008
Read more
USING LASER THERAPY FOR DIABETIC MACULOPATHY AND AMD
Ophthalmology Times, November 2007
Read more
IRV ARONS' JOURNAL
Irving Arons spent more than 30 years as a consultant to the ophthalmology industry, and more than 20 years as a medical laser industry consultant before retiring in 2005. Since then, he has continued to follow and comment on notable industry research, events and other topics in his blog, “Irv Aron’s Journal.” Late in 2007, he included a lengthy entry about 2RT research, writing, in part, “In looking further into this technique, I became convinced that, although it was very early in its development, it held the potential to become an important treatment in the armamentarium of retinal physicians."
Read the entire blog entry here.
Register
Would you like to be updated on 2RT Research? Register here and we will send you updates on Ellex's clinical progress.
|
